AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

https://x.com/brooks_david3/status/1923135945265533354?s=46&t=duv9CfL9-Llr6qyIetiHDA

https://investors.abcellera.com/news/news-releases/2025/AbCellera-Receives-Authorization-from-Health-Canada-to-Initiate-the-Phase-1-Clinical-Trial-of-ABCL635-for-Vasomotor-Symptoms-Due-to-Menopause/default.aspx

https://www.businesswire.com/news/home/20250512115715/en/AbCelleras-Microfluidic-Cell-Culture-Patent-Affirmed-Valid-by-the-U.S.-Court-of-Appeals-for-the-Federal-Circuit

AbCellera Biologics (ABCL) In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on AbCellera Biologics. The company’s shares closed last Thursday at $2.01. According to TipRanks.com, Smith is a 1-star analyst with an average return of -4.2% and a 37.5% success rate. Smith covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and Ginkgo Bioworks Holdings. Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $11.40. https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mind-medicine-mnmd-and-abcellera-biologics-abcl?mod=mw_quote_news

Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News GuruFocus News May. 9, 2025 at 11:46 a.m. ET Stifel has revised its price target for AbCellera (ABCL, Financial), reducing it from $10 to $8 while maintaining a Buy rating. The adjustment comes as the company prepares for a Phase 1 trial of ABCL635, which targets NK3R. This development is seen as promising, potentially positioning ABCL635 as a safer and more convenient treatment option. The update follows the company's recent earnings announcement and corporate developments.

May 9, 2025 2:09 PM Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul by Vandana Singh Benzinga Editor On Thursday, U.S. Food and Drug Administration (FDA) Commissioner Martin A. Makary announced an aggressive timeline to scale the use of artificial intelligence (AI) internally across all FDA centers by June 30, following the completion of a new generative AI pilot for scientific reviewers. Makary has directed all FDA centers to begin deployment immediately, with the goal of full integration by the end of June. Work will continue to expand use cases, improve functionality, and adapt to the evolving needs of each center after June 30. By that date, all centers will be operating on a common, secure generative AI system integrated with the FDA’s internal data platforms. Makary spoke about the need to shorten the length of the drug approval process and the use of artificial intelligence, among other topics, during the AHA Annual Membership Meeting on Tuesday. “We at the FDA now have to ask big questions that we’ve never asked before,” Makary said. “Why does it take over 10 years for a new drug to come to market? Why are we not modernized with AI and other things?” Makary was also optimistic about AI helping to approve new treatments for conditions such as diabetes and certain types of cancer. According to a media report on Wednesday, OpenAI, which is backed by Microsoft Corp, met with FDA officials to discuss the agency’s use of AI to speed up drug evaluations. Makary didn’t say OpenAI was involved in the project, but sources familiar with it say a small team from OpenAI has met several times in recent weeks with the FDA and two associates from Elon Musk’s Department of Government Efficiency (DOGE). They’ve been discussing a project called “cderGPT,” likely referring to the FDA’s Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs in the U.S., and “Research GPT.” Jeremy Walsh, the FDA’s newly appointed AI officer, has led the talks. No contract has been finalized yet. According to the May 2024 McKinsey Global Institute report, AI technology could generate $60 billion—$110 billion annually in economic value for the pharmaceutical industry, as it can help speed up the process of identifying compounds, their development, and approval. In May 2024, Researchers at Alphabet Inc.’s Google DeepMind developed AlphaFold 3, a new artificial intelligence (AI) model. AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA, and RNA, and small molecules that could function as drugs. Google DeepMind will make the model available for non-commercial use through the AlphaFold server.

Wie sweet 4,24 Mio. 🤣😭

Hier auf dem Level zu kaufen ist ein geschenk.

Was 😮, ich habe ordentlich nachgelegt. Ich dachte man kauft Aktien wenn der Preis unten ist um sie wieder zu verkaufen wenn der Preis oben ist. 🤔

Den das Unternehmen geht in 2 Jahren pleite

Keine Panik leute ich verspreche euch eins nicht nachkaufen

Abcellera ist das Unternehmen wo jeder investieren muss um Geld zu verlieren 😂🫡

Wieviele hast du aktuell

Ich gehe auf Risiko und Kaufe weiter 🤩

Und was jetzt abcellera biologics wird bald Insolvenz oder